Entries by CAPTIS

FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC

The therapy is approved for patients with squamous or non-squamous disease and regardless of PD-L1 expression. This application was reviewed under the FDA’s Real-Time Oncology Review (RTOR) pilot The post FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC appeared first on Pharmaceutical Business review.

Merck to acquire Austrian vaccine maker Themis Bioscience

Themis Bioscience is said to have a pipeline of vaccine candidates and immune-modulatory therapies, which have been developed using its measles virus vector platform. In March 2020, the The post Merck to acquire Austrian vaccine maker Themis Bioscience appeared first on Pharmaceutical Business review.

Shionogi to buy Tetra Therapeutics in $500m deal

The deal value of $500m will be based on the achievement of certain predetermined regulatory and commercial milestones. The transaction will provide Shionogi with global rights to Tetra’s The post Shionogi to buy Tetra Therapeutics in $500m deal appeared first on Pharmaceutical Business review.

FDA approves Dupixent as first biologic medicine for children aged six to 11 years with moderate-to-severe atopic dermatitis

“This FDA approval is another milestone in the journey for Dupixent as an innovative biologic treatment for atopic dermatitis and other conditions driven in part by type 2 The post FDA approves Dupixent as first biologic medicine for children aged six to 11 years with moderate-to-severe atopic dermatitis appeared first on Pharmaceutical Business review.

Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on secondary endpoints

Importantly, the final trial results have also confirmed the drug’s positive effects on the secondary trial endpoints that assessed the drug’s activity and efficacy including measuring the effects The post Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on secondary endpoints appeared first on Pharmaceutical Business review.